Abstract:Objective: The IMpassion 031 and KEYNOTE-355 clinical trial demonstrated the advantages of atezolizumab and pembrolizumab in the treatment of Triple-negative breast cancer (TNBC). However, the application of CPS in assessing PD-L1 expression is challenging. Pathologists have great variability in interpretation of PD-L1 CPS, the daily diagnostic workload is too heavy and their diagnostic efficiency is low, and they still have deficiencies in terms of accurate enumeration. It is of necessity to establish an objective and effective method which is highly repeatable. Methods: In this study, we established a deep learning-based artificial intelligence-assisted (AI-assisted) model which using cell detection and region segmentation algorithm. Three rounds of ring studies (RSs) were conducted. 12 pathologists of different level evaluate the CPS of PD-L1 (DAKO 22C3) in TNBC patients by visual assessment and AI-assisted model. Compare the difference, consistency and accuracy of the interpretation. Our research evaluated PD-L1 CPS expression with continuous score. Shapiro-Wilk (S-W) method performs normality test, difference analysis using Friedman M and Bonferroni calibration tests, consistency analysis is studied by intraclass correlation coefficient (ICC) and heat maps and box plots. Results: In the visual assessment, the interpretation results of PD-L1 (DAKO 22C3) CPS in different level pathologists have significant differences (P < 0.05), and the consistency of all the pathologists interpretation results was weak. Due to this strong inconsistency, it may result in a number of patients losing the opportunity to use ICIs for treatment. Moreover, the internal consistency of all pathologists in the visual assessment is moderate, in which the repeatability of junior pathologists is the worst, the ICC value is 0.664 (95%CI: 0.564-0.762). Through AI-assisted interpretation, there is no significant difference between all pathologists (P = 0.425), and the ICC value increased to 0.883 (95%CI:0.836-0.922) which improved the consistency of the interpretation results. In addition, through AI-assisted interpretation, the repeatability and accuracy of the interpretation results has been further upgraded. At the same time, the acceptance of AI results by junior pathologists are high, and 80% of the AI results are accepted. Conclusions: With the help of the AI-assisted diagnostic model, different levels of all the pathologists have achieved excellent consistency and repeatability in the interpretation of PD-L1 (DAKO 22C3) CPS. Moreover, the level of interpretation has been sought the rapid enhancement. It can be seen that AI-assisted diagnostic model provides a good approach to strengthen the consistency and repeatability in clinical practice. Our research also shows that PD-L1 CPS can receive precise interpretation from pathologists, so more patients have the opportunity to use ICIs. Therefore, these patients can benefit from treatment and achieve better survival. The interpretation results and system diagram of PD-L1 CPS by AI-assisted model. The consistency and repeatability of the interpretation results. (A)-(C) The consistency of the PD-L1 CPS interpretation among the different level of pathologists in three ring studies. (D)The repeatability of the interpretation results between 12 pathologists in RS1 and RS2. Accuracies and acceptance rates of different experienced pathologists. (A) Boxplots of scoring accuracies for pathologists in different levels. (B) Acceptance rates of all pathologists in total 50 slides. (C) Percent stacked column chart of different levels of pathologists with AI score acceptance. Citation Format: Jinze Li, Xinran Wang, Yueping Liu. AI-assisted interpretation of PD-L1 CPS improves the precision medicine in Triple-negative breast cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl) nr PO5-07-02.

Abstract 471: AIM PD-L1-NSCLC: Artificial intelligence-powered PD-L1 quantification for accurate prediction of tumor proportion score in diverse, multi-stain clinical tissue samples

Abstract CT112: AI-powered and manual assessment of PD-L1 are comparable in predicting response to neoadjuvant atezolizumab in patients (pts) with resectable non-squamous, non-small cell lung cancer (NSCLC)

A New AI-assisted Scoring System for PD-L1 expression in NSCLC

Association of Artificial Intelligence-Powered and Manual Quantification of Programmed Death-Ligand 1 (PD-L1) Expression with Outcomes in Patients Treated with Nivolumab ± Ipilimumab

Abstract PO5-07-02: AI-assisted interpretation of PD-L1 CPS improves the precision medicine in Triple-negative breast cancer

AI based PD-L1 CPS quantifier software to identify more patients for checkpoint therapy in gastric cancer at pathologist-level interobserver concordance.

Abstract 6172: Accurate PD-L1 IHC assessment in urothelial carcinoma by an AI algorithm robust across multiple sites, antibody clones, and scanners

Abstract 7402: Foundation AI models predict molecular measurements of tumor purity

Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer

Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments

Abstract 7617: Quantitative continuous scoring of PD-L1 for superior patient selection for anti-PD-L1 treatment of locally advanced or unresectable NSCLC

Abstract 2492: Enhanced patient selection for anti-PD-L1 treatment in metastatic NSCLC with quantitative continuous scoring of PD-L1

Assessment of PD-L1 expression and tumour infiltrating lymphocytes in early-stage non-small cell lung carcinoma with artificial intelligence algorithms

Abstract 4170: Artificial intelligence (AI)-based multi-modal approach using H&E and CT image for predicting treatment response of immune checkpoint inhibitor (ICI) in non-small cell lung cancer (NSCLC)

Abstract 5139: PD1-PDL1 interaction as a superior predictor for response to immune checkpoint therapy in NSCLC patients

Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study

Artificial Intelligence-Assisted Score Analysis for Predicting the Expression of the Immunotherapy Biomarker PD-L1 in Lung Cancer

Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer

Abstract 6189: Deep-learning model trained on multiplex immunofluorescence-stained tissue samples predicts the survival of patients with non-small cell lung cancer better than PD-L1 TPS alone

Abstract 912: CheckpointPx, an interpretable radiology AI tool, predicts checkpoint blockade benefit independent of PDL1 status in non-small cell lung cancers (NSCLC): A multi-institutional validation study

Abstract PO4-26-01: Computational pathology: Revolutionizing diagnostics and clearing the way for precision medicine